Caffeic Acid N-[3,5-Bis(Trifluoromethyl)Phenyl] Amide as a Non-Steroidal Inhibitor for Steroid 5α-Reductase Type 1 Using a Human Keratinocyte Cell-Based Assay and Molecular Dynamics

December 2022 in “ Scientific Reports ”

Aye Chan Khine Lin, Ponsawan Netcharoensirisuk, Kamonpan Sanachai, Warongrit Sukma, Chaisak Chansriniyom, Chatchai Chaotham, Wanchai De-Eknamkul, Thanyada Rungrotmongkol, Supakarn Chamni

caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide steroid 5α-reductase type 1 SRD5A1 androgenic alopecia human keratinocyte cells HaCaT cells avicequinone C finasteride dutasteride molecular dynamics simulations dihydrotestosterone DHT compound 4 Propecia Avodart

From the encyclopedia

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Studysummary This study found that caffeic acid amide derivative, compound 4, effectively inhibited steroid 5α-reductase type 1 in vitro, suggesting potential for development as a treatment for androgenic alopecia.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on nature.com →

Discuss this study in the Community →

Research cited in this study

27 / 27 results

research Physcion, a Novel Inhibitor of 5α-Reductase That Promotes Hair Growth In Vitro and In Vivo

18 citations , February 2021 in “Archives of Dermatological Research”

This study found that Physcion from Polygonum multiflorum may be an effective natural 5α-reductase inhibitor for treating androgenic alopecia by enhancing hair growth and improving follicle morphology in laboratory settings.

research Structure of Human Steroid 5α-Reductase 2 with the Anti-Androgen Drug Finasteride

30 citations , October 2020 in “Nature Communications”

This study provides the first crystal structure of the human SRD5A2 enzyme, revealing key insights into its function and inhibition which may aid future drug development.

research 5-Alpha Reductase Inhibitors in Androgenetic Alopecia: Shifting Paradigms, Current Concepts, Comparative Efficacy, and Safety

19 citations , April 2020 in “Dermatologic Therapy”

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

research Female Androgenetic Alopecia: An Update on Diagnosis and Management

43 citations , November 2019 in “American Journal of Clinical Dermatology”

This review discusses female androgenetic alopecia, highlighting its diagnostic challenges and management strategies, but it reports no new results.

The Efficacy and Safety of Dutasteride Compared with Finasteride in Treating Men with Androgenetic Alopecia: A Systematic Review and Meta-Analysis

research The Efficacy and Safety of Dutasteride Compared with Finasteride in Treating Men with Androgenetic Alopecia: A Systematic Review and Meta-Analysis

38 citations , February 2019 in “Clinical Interventions in Aging”

This meta-analysis found that dutasteride was more effective than finasteride in increasing hair count and improving photographic assessments for men with androgenetic alopecia, while both drugs had similar rates of sexual dysfunction-related adverse effects.

research Discovery of Natural Steroid 5 Alpha-Reductase Inhibitors

11 citations , December 2018 in “Assay and Drug Development Technologies”

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

research Anti-Androgenic Curcumin Analogues as Steroid 5-Alpha Reductase Inhibitors

12 citations , March 2017 in “Medicinal Chemistry Research”

This study found that certain curcumin analogs derived from natural plant sources exhibit anti-androgen activity by inhibiting steroid 5-alpha reductase, identifying key structural features for their potency and safety in treating androgen-related conditions.

research Synthesis, Biological Evaluation and Molecular Docking of Avicequinone C Analogues as Potential Steroid 5α-Reductase Inhibitors

13 citations , January 2017 in “Chemical & Pharmaceutical Bulletin”

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.

Identification of a New Plant Extract for Androgenic Alopecia Treatment Using a Non-Radioactive Human Hair Dermal Papilla Cell-Based Assay

research Identification of a New Plant Extract for Androgenic Alopecia Treatment Using a Non-Radioactive Human Hair Dermal Papilla Cell-Based Assay

17 citations , December 2015 in “BMC Complementary and Alternative Medicine”

This study found that Avicennia marina extract significantly inhibited 5α-reductase type 1 activity in human hair dermal papilla cells, suggesting its potential use for treating androgenic alopecia.

Inhibition of Rat 5α-Reductase Activity and Testosterone-Induced Sebum Synthesis in Hamster Sebocytes by an Extract of Quercus Acutissima Cortex

research Inhibition of Rat 5α-Reductase Activity and Testosterone-Induced Sebum Synthesis in Hamster Sebocytes by an Extract of Quercus Acutissima Cortex

37 citations , January 2015 in “Evidence-based Complementary and Alternative Medicine”

This study found that Bokusoku extract and its compound pentagalloyl glucose inhibited testosterone metabolism and sebum synthesis, suggesting potential therapeutic use for androgen-related acne.

research Stimulatory Effect of Brazilian Propolis on Hair Growth Through Proliferation of Keratinocytes in Mice

18 citations , November 2014 in “Journal of Agricultural and Food Chemistry”

This study found that ethanol-extracted propolis stimulated hair growth in mice by promoting the proliferation of hair keratinocytes.

research Potential Targets in the Discovery of New Hair Growth Promoters for Androgenic Alopecia

59 citations , May 2014 in “Expert Opinion on Therapeutic Targets”

This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.

Avicequinone C Isolated from Avicennia Marina Exhibits 5α-Reductase Type 1 Inhibitory Activity Using an Androgenic Alopecia Relevant Cell-Based Assay System

research Avicequinone C Isolated from Avicennia Marina Exhibits 5α-Reductase Type 1 Inhibitory Activity Using an Androgenic Alopecia Relevant Cell-Based Assay System

19 citations , May 2014 in “Molecules”

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.

research Androgenetic Alopecia: An Evidence-Based Treatment Update

151 citations , May 2014 in “American Journal of Clinical Dermatology”

This review concluded that oral finasteride for men and topical minoxidil for both genders have the most evidence supporting their effectiveness and safety for treating androgenetic alopecia.

research Synthesis and 5α-Reductase Inhibitory Activity of C21 Steroids Having 1,4-Diene or 4,6-Diene 20-Ones and 4-Azasteroid 20-Oximes

186 citations , December 2011 in “Molecules”

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

research The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases

218 citations , December 2011 in “Advances in Urology”

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.

research Inhibitory Activities of Puerariae Flos Against Testosterone 5α-Reductase and Its Hair Growth Promotion Activities

34 citations , August 2011 in “Journal of Natural Medicines”

This study found that Puerariae Flos extract inhibited testosterone 5α-reductase and promoted hair growth in mouse models, suggesting its potential use for treating androgenic alopecia.

research An Overview on 5α-Reductase Inhibitors

219 citations , October 2009 in “Steroids”

5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.

research Testosterone 5-Alpha-Reductase Inhibitory Active Constituents of Piper Nigrum Leaf

44 citations , January 2007 in “Biological & pharmaceutical bulletin”

This study found that Piper nigrum leaf extract showed in vivo anti-androgenic activity and potent 5α-reductase inhibitory effects, with piperine and (−)-cubebin identified as active components.

research Novel 5α-Reductase Inhibitors: Synthesis, Structure-Activity Studies, and Pharmacokinetic Profile of Phenoxybenzoylphenyl Acetic Acids

18 citations , December 2005 in “Journal of Medicinal Chemistry”

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

research New 5α-Reductase Inhibitors: In Vitro and In Vivo Effects

45 citations , February 2005 in “Steroids”

This study reported that certain newly synthesized steroidal derivatives showed stronger inhibitory activity against the 5α-reductase enzyme than finasteride in hamsters, suggesting their potential as enzyme inhibitors.

research Selective Non-Steroidal Inhibitors of 5α-Reductase Type 1

49 citations , January 2004 in “Journal of steroid biochemistry and molecular biology/The Journal of steroid biochemistry and molecular biology”

This review discusses the development and selectivity of 5 alpha-reductase inhibitors, particularly non-steroidal ones, and reports no new clinical trial results.

research Inhibitors of 5α-Reductase Type I in LNCaP Cells from the Roots of Angelica Koreana

22 citations , February 2002 in “Planta Medica”

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

Different Levels of 5α-Reductase Type I and II, Aromatase, and Androgen Receptor in Hair Follicles of Women and Men with Androgenetic Alopecia

research Different Levels of 5α-Reductase Type I and II, Aromatase, and Androgen Receptor in Hair Follicles of Women and Men with Androgenetic Alopecia

416 citations , September 1997 in “Journal of Investigative Dermatology”

People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.

Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

research Mechanism-Based Inhibition of Human Steroid 5α-Reductase by Finasteride: Enzyme-Catalyzed Formation of NADP-Dihydrofinasteride, a Potent Bisubstrate Analog Inhibitor

136 citations , March 1996 in “Journal of the American Chemical Society”

This study explains finasteride's high potency and specificity as a mechanism-based inhibitor for treating benign prostatic hyperplasia by detailing its interaction with human type 2 steroid 5α-reductase.

research The Enzyme and Inhibitors of 4-Ene-3-Oxosteroid 5α-Oxidoreductase

64 citations , June 1995 in “Steroids”

This review discusses biochemical studies on 5 alpha-reductase and its inhibitors, comparing IC50 and Ki values for various compounds, but reports no new experimental results.

research Role of 5α-Reductase in Health and Disease

101 citations , April 1994 in “Baillière's clinical endocrinology and metabolism”

This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.